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Abstract
Background A three-pronged approach to acne treatment—combining an antibiotic, antibacterial, and retinoid—could
provide greater efficacy and tolerability than single or dyad treatments, while potentially improving patient compliance and
reducing antibiotic resistance.
Objectives We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate
1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne.
Methods In a phase II, double-blind, multicenter, randomized, 12-week study, eligible participants aged ≥ 9 years with
moderate-to-severe acne were equally randomized to once-daily IDP-126, vehicle, or one of three component dyad gels:
BPO/adapalene; clindamycin phosphate/BPO; or clindamycin phosphate/adapalene. Coprimary endpoints were treatment
success at week 12 (participants achieving a ≥ 2-grade reduction from baseline in Evaluator’s Global Severity Score and
clear/almost clear skin) and least-squares mean absolute changes from baseline in inflammatory and noninflammatory lesion
counts to week 12. Treatment-emergent adverse events and cutaneous safety/tolerability were also assessed.
Results A total of 741 participants were enrolled. At week 12, 52.5% of participants achieved treatment success with IDP126 vs vehicle (8.1%) and dyads (range 27.8–30.5%; P ≤ 0.001, all). IDP-126 also provided significantly greater absolute
reductions in inflammatory (29.9) and noninflammatory (35.5) lesions compared with vehicle or dyads (range inflammatory,
19.6–26.8; noninflammatory, 21.8–30.0; P < 0.05, all), corresponding to > 70% reductions with IDP-126. IDP-126 was well
tolerated, with most treatment-emergent adverse events of mild-to-moderate severity.
Conclusions Once-daily treatment with the novel fixed-dose triple-combination clindamycin phosphate 1.2%/BPO 3.1%/
adapalene 0.15% gel demonstrated superior efficacy to vehicle and all three dyad component gels, and was well tolerated
over 12 weeks in pediatric, adolescent, and adult participants with moderate-to-severe acne.
Clinical Trial Registration ClinicalTrials.gov identifier NCT03170388 (registered 31 May, 2017).

1 Introduction
The pathogenesis of acne, one of the most common dermatologic disorders, is a multifactorial process involving
follicular proliferation of Cutibacterium acnes (formerly
Propionibacterium acnes), abnormal keratinization, and
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increased sebum production and inflammation [1, 2]. Effective treatment, which requires pharmacologic targeting of
one or more of these pathophysiologic mechanisms, includes
various prescription oral and topical treatments such as benzoyl peroxide (BPO), retinoids (topical tretinoin, adapalene,
tazarotene, trifarotene; oral isotretinoin), antibiotics (e.g.,
erythromycin, clindamycin, minocycline, doxycycline, sarecycline), and hormonal therapies [2]. Adherence rates to oral
or topical acne treatments, however, are typically poor and
reasons for low adherence include complex regimens, lack
of efficacy, and adverse effects [3, 4]. Combining treatments
Vol.:(0123456789)
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Key Points
Combining three acne treatments (an antibiotic, antibacterial, and retinoid) within an easy-to-use topical formulation could improve efficacy, tolerability, and treatment
adherence. This is the first study of clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%
(IDP-126) gel, which once approved will be the first
triple-combination, fixed-dose topical acne treatment.
Results from this multi-center, randomized, double-blind
study in children, adolescents, and adults with moderateto-severe acne showed that over half of participants
treated with IDP-126 gel achieved treatment success by
week 12, with over 70% reductions in inflammatory and
noninflammatory lesions.
Overall, IDP-126 demonstrated significantly greater
efficacy vs vehicle gel and the three component dyad
gels and was well tolerated over 12 weeks of daily use—
making it a potential new treatment option in the acne
armamentarium.

in an easy-to-use, fixed-dose formulation can improve treatment adherence by reducing complex drug regimens [3, 5].
Furthermore, combining topical treatments that target multiple processes of acne pathogenesis may improve efficacy [6]
and is a recommended treatment strategy for the majority of
patients with acne per the US treatment guidelines published
in 2016 [2].
Clindamycin phosphate 1.2%/BPO 3.1%/adapalene
0.15% gel (IDP-126), once approved, will be the first triplecombination fixed-dose topical acne treatment. Formulated
as an aqueous gel, with no alcohol, preservatives, occlusive agents, or surfactants, it is pH balanced for the skin
and contains propylene glycol, a hydrating humectant. As
a smaller particle size allows for better penetration of the
pilosebaceous unit [7, 8], BPO and adapalene have been
micronized. Additionally, all ingredients are contained
within a polymeric gel to allow for even distribution on the
skin. As vehicle formulation can affect the tolerability of
topical treatments [7], the use of micronized ingredients
contained within a polymeric gel may also provide better
tolerability. Although combining multiple acne treatments
into one formulation can be difficult, as some retinoids, such
as tretinoin, are more susceptible to oxidative breakdown in
the presence of BPO, adapalene is more stable than tretinoin
under such conditions [9].
Several dyad formulations containing BPO/adapalene
or BPO/clindamycin have been approved in the USA [10],

but IDP-126 will be the first to combine all three ingredients. While the dyad combinations of BPO with adapalene
or clindamycin result in greater lesion reductions than the
individual treatments alone, irritation may be an issue with
certain combinations [11–14]. Improved efficacy has also
been demonstrated following the use of BPO/clindamycin in
the morning with the retinoid tazarotene in the evening [15],
though complex regimens can impact patient adherence. The
objective of this phase II study was to evaluate the efficacy,
safety, and tolerability of IDP-126, a novel once-daily clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% fixeddose gel, in patients with moderate-to-severe acne.

2 Methods
2.1 Study Design
In this phase II, multicenter, randomized, double-blind,
parallel-group, vehicle-controlled study, participants 9 years
of age or older with moderate (Evaluator’s Global Severity
Score [EGSS] 3) or severe (EGSS 4) acne were enrolled
from 31 study centers in the USA and four in Canada. Eligible participants also needed to have the following facial
lesions: ≥ 30 to ≤ 100 inflammatory (pustules, papules,
and nodules), ≥ 35 to ≤ 150 noninflammatory (closed and
open comedones), and two or fewer nodules. Ranges were
selected to enroll patients with a baseline number of lesions
while minimizing large variations across the treatment arms.
CeraVe® hydrating cleanser, CeraVe® moisturizing lotion
(L’Oreal, New York, NY, USA), and sunscreen were provided as needed for optimal moisturization/cleaning of the
skin.
Participants were equally randomized to receive one of
five treatments to be applied to the face once daily for 12
weeks: clindamycin phosphate 1.2%/BPO 3.1%/adapalene
0.15% gel (IDP-126); one of the three component dyads
formulated with the same active drug concentration and
within the same vehicle as IDP-126 (BPO 3.1%/adapalene
0.15% gel; clindamycin phosphate 1.2%/BPO 3.1% gel;
clindamycin phosphate 1.2%/adapalene 0.15% gel); or
vehicle gel. Identically labeled/packaged study drug kits
were dispensed to participants at baseline and weeks 4
and 8 by study center staff, based on a randomization code
assigned by the central randomization system. This study
was carried out in accordance with principles of Good
Clinical Practice and the Declaration of Helsinki. At all
investigational sites, the study protocol was approved by
the relevant independent ethics committees or institutional
review boards. All participants or their legal guardians
provided written informed consent.
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2.2 Study Assessments
Efficacy evaluations comprised counts of inflammatory and
noninflammatory lesions and treatment success, defined as
the proportion of participants achieving a ≥ 2-grade reduction from baseline in EGSS and a score of 0 (clear) or 1
(almost clear). Assessments were performed at screening,
baseline, and weeks 2, 4, 8, and 12 (treatment end). The
EGSS was scored as follows: 0 = Normal, clear skin with
no evidence of acne; 1 = Rare noninflammatory lesions
present, with rare noninflamed papules (papules must be
resolving and may be hyperpigmented, though not pinkred); 2 = Some noninflammatory lesions are present, with
few inflammatory lesions (papules/pustules only; no nodulocystic lesions); 3 = Noninflammatory lesions predominate, with multiple inflammatory lesions evident: several
to many comedones and papules/pustules, and there may
or may not be one nodulocystic lesion; 4 = Inflammatory
lesions are more apparent, many comedones and papules/
pustules, there may or may not be up to two nodulocystic
lesions. Participants also completed an Acne-Specific Quality of Life (Acne-QoL) questionnaire covering four domains
(self-perception, role-emotional, role-social, and acne
symptoms) at baseline and week 12; a higher score in any
domain indicates improved health-related quality of life [16].
Investigator-assessed cutaneous safety (scaling, erythema,
hypopigmentation, and hyperpigmentation) and participantreported tolerability (itching, burning, and stinging) were
evaluated via a 4-point scale where 0 = none and 3 = severe.
Treatment compliance was defined as participants missing
≤ 5 consecutive days of dosing and applying 80–120% of
expected applications. Adverse events (AEs) were evaluated
throughout the study.

treatment success and a ≥ 2-grade EGSS reduction, the Firth
option was added (used to apply Firth’s Penalized Likelihood to the logistic regression) because of convergence
issues.
For all efficacy assessments, values were adjusted for
multiple imputations and pairwise tests were performed to
compare IDP-126 with the three component dyads (BPO/
adapalene, clindamycin/BPO, clindamycin/adapalene) and
vehicle gel. Missing efficacy data were handled based on
estimation using the Markov Chain Monte Carlo multiple
imputation method. Acne-QoL questionnaire results and
cutaneous safety and tolerability assessments were summarized using descriptive statistics with no imputation of
missing values.
No formal sample size calculation was performed for this
study as the sample size was based only on clinical considerations and the numbers of participants enrolled in each
treatment arm were considered sufficient to evaluate the
safety and tolerability of IDP-126 vs the dyads or vehicle.
All statistical analyses were conducted using S
 AS® software,
version 9.3 or later (Cary, NC, USA). Statistical significance
was based on two-tailed tests of the null hypothesis resulting
in P ≤ 0.05. Adverse events were classified using the Medical Dictionary for Regulatory Activities terminology for
the safety population. No interim analyses were performed.
The intent-to-treat population consisted of all randomized
participants who received the study drug. The safety population was defined as all randomized participants who used the
study drug at least once and had at least one post-baseline
safety evaluation.

3 Results

2.3 Statistical Analyses

3.1 Participants

The coprimary endpoints were the percentage of participants
achieving treatment success at week 12 and the absolute
changes from baseline to week 12 in inflammatory and noninflammatory lesion counts. Treatment success at week 12
was analyzed using a logistic regression test with factors of
treatment group and analysis center. Significant skewness
was observed in the change from baseline analyses of noninflammatory and inflammatory lesions, and as such, a nonparametric method was used to rank transform the data prior
to the analysis of covariance. For the analysis of covariance,
treatment and analysis center were factors and the respective
baseline lesion counts were a covariate.
Secondary and post hoc analyses included treatment
success and a ≥ 2-grade reduction in EGSS by study visit,
percent changes from baseline in inflammatory and noninflammatory lesion counts by study visit, and quality-oflife assessments at week 12. For all post hoc analyses of

Screening began on 5 October, 2017 and the last study visit
occurred on 23 April, 2019. A total of 741 participants were
randomized to IDP-126, one of the three component dyad
gels, or vehicle gel, with 740 comprising the intent-to-treat
population (one excluded participant was not dispensed the
study drug; Fig. 1). Of these, ≥ 85% participants in each
treatment group completed the study. The most common
reasons for study discontinuation were AEs, lost to followup, and participant request. Discontinuation because of AEs
occurred in 0–5.3% of participants across treatments. A total
of 725 participants were included in the safety population.
Baseline demographics and disease characteristics are
shown in Table 1. Participants were similar across treatment arms: the mean age was approximately 19.5 years, the
majority were female (61.2%) and White (69.2%), and most
had moderate (EGSS 3) disease (range 79.3–86.0%). Treatment compliance across treatment groups was ≥ 93%.
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3.2 Efficacy and Quality of Life
Across all 12 coprimary efficacy comparisons, IDP-126
gel was significantly more efficacious than each of its dyad
components and vehicle (Table 2). Over half of participants (52.5%) achieved treatment success at week 12 with
IDP-126, significantly greater than the three dyad gels
(range 27.8–30.5%; P ≤ 0.001, all) and vehicle gel (8.1%;
P < 0.001). Absolute mean reductions in inflammatory and
noninflammatory lesions from baseline to week 12 were also
significantly greater with IDP-126 vs all dyads and vehicle
(Table 2).
In the by-study visit analyses, significant differences in
treatment success were seen as early as week 4 with IDP126 vs vehicle (P < 0.01) and maintained throughout the
study (see eFig. 1 of the Electronic Supplementary Material [ESM]). By study end, over half of IDP-126-treated
participants (58.7%) also achieved a ≥ 2-grade reduction
from baseline in EGSS, significantly more than the three
dyads (35.8–37.0%) and vehicle (12.5%; P ≤ 0.001, all).
In terms of least-squares mean percent changes in acne
lesion counts, IDP-126 had significantly greater reductions
in inflammatory and noninflammatory lesions than vehicle
gel at all study visits (P < 0.05, all), with over 70% reductions achieved by week 12 (Fig. 2). Additionally, significant

Fig. 1  Participant disposition. aWithdrawal by parent or guardian. bOne excluded participant was not dispensed the study drug.
c
Excluded participants had no post-baseline safety evaluations. ADAP

differences between IDP-126 and each of its component
dyads were observed at week 12 (Fig. 2 footnote). Images
depicting acne improvement in IDP-126-treated participants
are shown in Fig. 3. Improvements in Acne-QoL scores at
week 12 were numerically greater for the IDP-126 group vs
all three dyad gels and vehicle in all four domains, with the
largest improvements seen in the domains of self-perception
and role-emotional (Fig. 4).

3.3 Safety
A greater proportion of participants treated with IDP-126
and BPO/adapalene reported treatment-emergent AEs
(TEAEs) compared with clindamycin/BPO, clindamycin/
adapalene, or vehicle (Table 3). Treatment-emergent AEs
were mostly mild or moderate in severity for all groups and
more TEAEs were considered related to treatment in the
IDP-126 and BPO/adapalene groups. The most commonly
reported TEAEs related to treatment were application-site
pain and dryness. A total of four participants experienced
one serious AE each, none of which was considered related
to treatment (n = 1 in IDP-126 group [sickle cell anemia
with crisis]; n = 3 in clindamycin/adapalene [enteritis;
hyperbilirubinemia; induced abortion]). Discontinuations
because of TEAEs were highest in the BPO/adapalene group

adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin
phosphate 1.2%, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, ITT intent to treat
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Table 1  Baseline demographics and characteristics (ITT population)

Age, mean (SD), y
Age, median (range), y
Female, n (%)
Ethnicity, Hispanic/Latino, n (%)
Race, n (%)
Black
White
Asian
Othera
Inflammatory lesion count, mean (SD)
Noninflammatory lesion count, mean (SD)
Evaluator’s Global Severity Score, n (%)
3: moderate
4: severe

IDP-126 gel (n = 146)

BPO/ADAP
gel (n = 150)

CLIN/BPO
gel (n = 146)

CLIN/ADAP
gel (n = 150)

Vehicle gel (n = 148)

19.9 (7.0)
17.0 (11–46)
94 (64.4)
33 (22.6)

19.2 (8.0)
17.0 (10–60)
86 (57.3)
30 (20.0)

19.6 (6.9)
17.0 (10–45)
91 (62.3)
29 (19.9)

19.4 (6.5)
17.0 (11–50)
93 (62.0)
27 (18.0)

19.6 (7.1)
17.0 (11–47)
89 (60.1)
34 (23.0)

24 (16.4)
98 (67.1)
10 (6.8)
14 (9.6)
39.0 (11.8)
51.8 (20.3)

26 (17.3)
109 (72.7)
6 (4.0)
9 (6.0)
39.0 (10.2)
48.0 (14.7)

30 (20.5)
101 (69.2)
8 (5.5)
7 (4.8)
40.0 (12.8)
49.2 (17.6)

20 (13.3)
109 (72.7)
9 (6.0)
12 (8.0)
38.2 (7.9)
51.1 (18.4)

26 (17.6)
95 (64.2)
17 (11.5)
10 (6.8)
38.2 (9.2)
50.7 (18.7)

124 (84.9)
22 (15.1)

119 (79.3)
31 (20.7)

124 (84.9)
22 (15.1)

129 (86.0)
21 (14.0)

127 (85.8)
21 (14.2)

ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, ITT intent to treat, SD standard deviation
a

American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and other/multiple

Table 2  Coprimary endpoints at week 12 (ITT population)
IDP-126 gel (n =
146)
Treatment successa, %
Absolute change from baseline,
LS mean
Inflammatory lesions
Noninflammatory lesions

52.5

− 29.9
− 35.5

BPO/ADAP gel (n
= 150)
27.8***

− 26.7*
− 29.9**

CLIN/BPO gel (n
= 146)

CLIN/ADAP gel (n
= 150)

30.5***

− 24.8**
− 27.8***

30.3***

− 26.8*
− 30.0**

Vehicle gel (n = 148)
8.1***

− 19.6***
− 21.8***

Multiple imputation was used to impute missing values
ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, EGSS Evaluator’s Global Severity Score, IDP-126
clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, ITT intent to treat, LS least squares
*P < 0.05; **P < 0.01; ***P ≤ 0.001 vs IDP-126
a

Defined as a ≥ 2-grade reduction from baseline in EGSS and a score of 0 (clear) or 1 (almost clear)

(Table 3). A total of five participants experienced a system
organ class gastrointestinal disorder AE (one participant in
the clindamycin/adapalene group had two AEs): one constipation (IDP-126); one gastritis (IDP-126); one dyspepsia
(clindamycin/adapalene); one enteritis (clindamycin/adapalene); one vomiting (clindamycin/adapalene); and one
diarrhea (vehicle). None of these AEs was considered by
the investigator to be related to treatment and all were mild
to moderate in severity with the exception of enteritis.
Across all active treatment groups, there were transient
increases in severity from baseline at weeks 2 or 4 for

several of the cutaneous safety and tolerability assessments
(see eFig. 2 of the ESM). Mean scores for all treatments
at all visits, however, were ≤ 0.6 (score of 1 = mild). By
week 12, < 6% of participants in any treatment group experienced a severe rating on any cutaneous safety or tolerability
assessment; participant-reported burning and stinging had
the highest rates of severe events, both of which were highest in the BPO/adapalene group (Table 3). In the IDP-126
group, there were no reports of severe scaling, erythema,
hypopigmentation, and itching and < 5% of participants
reported severe hyperpigmentation, burning, and stinging.
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Fig. 2  Least-squares (LS) mean percent reductions in a inflammatory lesions and b noninflammatory lesions (intent-to-treat [ITT]
population). Multiple imputation was used to impute missing values.
*P < 0.05; ***P < 0.001 vehicle vs clindamycin phosphate 1.2%/
benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126). Data not shown:
P-values for IDP-126 vs dyads were significant (P < 0.05) as follows: inflammatory lesions: benzoyl peroxide 3.1%, (BPO)/adapalene
0.15% (ADAP) at weeks 2, 4, 8, and 12; clindamycin phosphate
1.2%, (CLIN)/BPO at weeks 4 and 12; CLIN/ADAP at weeks 4, 8,
and 12. Noninflammatory lesions: BPO/ADAP at weeks 8 and 12;
CLIN/BPO at weeks and weeks 4, 8, and 12; CLIN/ADAP at weeks
4, 8, and 12. All active dyad treatments were significant vs vehicle at weeks 8 and 12 for both inflammatory and noninflammatory
lesions (P < 0.01, all); additionally, CLIN/BPO and CLIN/ADAP
were significant vs vehicle at weeks 2 and 4 for inflammatory lesions
(P < 0.05, all) and BPO/ADAP and CLIN/ADAP were significant vs
vehicle at week 4 for noninflammatory lesions (P < 0.01, both)

4 Discussion
In this phase II study, IDP-126, the novel fixed-dose triplecombination clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel, was evaluated over 12 weeks in participants with moderate-to-severe acne. IDP-126 demonstrated
superior efficacy on all three coprimary endpoints compared
with the three dyad component combinations and vehicle gel
and was well tolerated.
The three drugs that make up IDP-126 were chosen in
order to target the multiple processes of acne pathogenesis.
Topical retinoids, such as adapalene, are a mainstay of acne
treatment; they normalize keratinocyte proliferation, block
several inflammatory pathways, promote comedolysis, and

reduce microcomedonal formation. While they are generally
well tolerated, their use can be limited by dryness, irritation,
and erythema [8, 17]. Adapalene—a third-generation retinoid that modulates cellular keratinization, differentiation,
and proliferation [8, 18]—has the advantage of being one of
the most tolerable retinoids [19] that also retains its stability
in the presence of BPO [9]. Benzoyl peroxide is an antibacterial agent with mild comedolytic activity, keratolytic
effects, and good efficacy and tolerability [2, 20–22]; it is
unaffected by C. acnes resistance, [20] and has been used in
combination with topical and oral antibiotics because of its
ability to reduce resistant C. acnes populations [23]. Topical
or oral antibiotics reduce C. acnes colonization and proliferation [24], and clindamycin, a lincosamide, is a widely
studied and commonly used antibiotic with anti-inflammatory effects [1]. It has been used for acne treatment for over
30 years [1] and has shown better efficacy in comparison to
erythromycin [2]. The addition of clindamycin to BPO not
only increases antibiotic activity [22], but may also moderate the irritating effects or withdrawals from AEs observed
with BPO [12, 14]. Altogether, the combination of these
three acne treatments targets three of the four acne pathogenic pathways and may reduce the antibiotic resistance and
adverse cutaneous effects observed with monotherapy.
In the present study, over half of IDP-126-treated participants achieved treatment success at week 12, with a rate that
was 1.7–1.8 times greater than with the component dyads.
The inclusion of all dyad combinations within the same
vehicle formulation as IDP-126 was a strength in this study,
in that it allowed for assessing the contribution of the active
drug components while minimizing study arms. However,
the exclusion of the component monads prevented the determination of the direct contributions of each active treatment
to calculate the synergistic treatment effect. Though synergy
cannot be directly assessed in this study, treatment success
rates with IDP-126 appeared to be greater than the expected
additive effect, as each of the dyad combinations had rates
less than two-thirds of IDP-126.
At week 12, IDP-126 demonstrated over 70% reductions
in acne lesions. Significantly greater percent reductions in
inflammatory and noninflammatory lesions were observed
as early as week 2 with IDP-126 vs vehicle gel, suggesting a
fast therapeutic action. As BPO, retinoids, and antibiotics act
primarily as antibacterial and/or anti-inflammatory agents,
it would be expected that inflammatory lesions would be
reduced more than noninflammatory lesions with IDP-126.
In this study, however, there were similar reductions in both
inflammatory and noninflammatory acne. This may be due
to the comedolytic properties of BPO as well as the ability of
clindamycin to reduce C. acnes populations. It is likely that
using these products together with adapalene targets both
inflammatory and noninflammatory acne. Similar results
were observed in a 12-week acne study where clindamycin/
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Fig. 3  Acne improvements with clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% (IDP-126). Individual results may vary.
EGSS Evaluator’s Global Severity Score (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe)

BPO gel was applied in the morning and tazarotene 0.1%
cream was also applied at night [25].
In context with other 10-week to 12-week clinical studies
that examined various combinations and dosages of commercially available dyads containing BPO and clindamycin
or adapalene, IDP-126 had greater numeric percent changes
in inflammatory and noninflammatory lesions (− 76.4% and
− 71.0%, respectively) than the other dyads (range − 42%
to − 68.7% and − 21.9% to − 68.3%) [11–13, 26–31]. IDP126 treatment success rates were also numerically greater
than dyads in other 12-week clinical studies (52.5% vs a
range of 21.5–33.7%) [13, 26–29]. As expected, the component dyads in the present study performed comparably to
other commercially available dyads, which further highlights
the efficacy of the triple-combination IDP-126 gel. Direct
comparisons, however, cannot be made between IDP-126
and other currently approved dyad treatments, as no headto-head or facial-splitting studies were conducted. Further,
there were design differences across the studies (phase II or

phase III; differing percentages of participants with moderate or severe acne and other patient backgrounds; differing
definitions of treatment success), as well as differences in
the drug dosages, combinations, and vehicle formulations.
Limitations of this study and its design are similar to
other clinical trials of acne. Assessments of acne severity
via the EGSS may result in inter-observer bias or variation.
Treatment duration in the study was limited to 12 weeks, and
longer treatment would better reflect real-world patient experiences. Finally, results from this study may not be generalizable to diverse real-world practice populations, which may
differ in race, age, and sex. Future post hoc analyses evaluating these populations of interest can address this limitation.
In the past, there has not been a formulation containing
BPO, a retinoid, and a topical antibiotic—possibly because
of concerns regarding tolerability (BPO and retinoids) and/
or antibacterial resistance (antibiotics). In the present study,
this triple combination demonstrated good tolerability with
once-daily use. As expected, there were slight increases from
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Fig. 4  Acne-Specific Quality of Life Questionnaire at week 12
(intent-to-treat population). No imputation of missing values. Higher
scores for each domain reflect improved health-related quality of life.
Self-perception domain assesses the extent facial acne has affected a
particular area of self-perception (e.g., feeling self-conscious, feeling
unattractive, dissatisfaction with self-appearance). Role-emotional
domain assesses the emotional effect or impact of facial acne (e.g.,
annoyance at spending time on face, worry/concern about medications working fast enough, bothersomeness of needing cover-up).

Role-social domain assesses the impact of facial acne on a respondent’s intersocial relationships (e.g., going out in public, meeting new
people, socializing). Acne symptoms assesses the physical symptoms
experienced by facial acne (e.g., bumps on face, scabbing, worry
about scarring); the acne symptom domain score correlates inversely
with acne severity. ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, IDP-126 clindamycin
phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%

baseline to week 12 in scaling, burning, and stinging mean
scores with IDP-126. Transient increases at weeks 2 and 4,
however, were lower with IDP-126 than the BPO/adapalene
dyad. Furthermore, there were no instances of severe scaling, erythema, or itching with IDP-126, whereas the BPO/
adapalene or clindamycin/adapalene dyads had instances of
severe ratings; IDP-126 also had fewer severe cases of burning and stinging than BPO/adapalene. Rates of discontinuations because of TEAEs were at least twofold higher with
BPO/adapalene than any of the other treatment groups.
The combination of clindamycin, BPO, and adapalene in
IDP-126 appears to have a slightly better safety and tolerability profile than the BPO/adapalene combination. This
may be a result of the IDP-126 vehicle formulation, the combination of active ingredients, or both. In terms of vehicle
formulation, as noted previously, IDP-126 is a gel that uses a
polymeric technology to provide a more uniform distribution
of all ingredients. It is also possible that the multiple antiinflammatory properties of clindamycin [1] can provide a
moderating effect on the cutaneous safety and tolerability of
BPO and adapalene. This rationale is supported by a metaanalysis that showed clindamycin combined with BPO had
lower odds of patient withdrawal/discontinuation because
of AEs than BPO alone or BPO/adapalene combinations
[14]. These results are supported by the AEs and AE-related
discontinuations reported in this phase II study, as well as

the cutaneous safety/tolerability data, as the lowest rates
of related AEs were observed with clindamycin/BPO and
the highest rates with BPO/adapalene. In addition, topical
antibiotics such as clindamycin are an attractive treatment
option as they may reduce the risk of systemic side effects
that are seen with oral antibiotics [2]. Though cases of diarrhea, bloody diarrhea, and colitis have been reported with
the use of clindamycin (oral or topical) [32], instances of
gastrointestinal AEs were rare in the present study and none
were deemed related to treatment.
An issue with common antibiotic acne treatments such as
erythromycin, clindamycin, and tetracyclines is the development of C. acnes resistance [2, 33]. While a topical minocycline 4% foam (approved in the USA for monotherapy) has
been introduced as having a decreased risk for the development of resistance, more research is needed to determine
the potential for the development of drug-resistant bacteria
with this formulation [34]. To prevent the development of
resistance, antibiotic monotherapy is not recommended [2,
35]. However, combining an antibiotic with BPO is recommended, as studies have shown that BPO reduces the risk of
antibiotic resistance [2, 23].
While there are many treatment options available, acne
is a chronic disease that requires long-term treatment [2,
4]. Regimens with side effects, low efficacy, or high complexity (e.g., using several treatments at one time, taking
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Table 3  Summary of AEs and safety/tolerability assessments
Participants, n (%)

IDP-126 gel
(n = 141)

BPO/ADAP gel
(n = 146)

CLIN/BPO gel
(n = 144)

CLIN/ADAP gel
(n = 148)

Vehicle gel
(n = 146)

Reporting any TEAE
51 (36.2)
52 (35.6)
26 (18.1)
40 (27.0)
22 (15.1)
Reporting any SAEa
1 (0.7)
0
0
3 (2.0)
0
8 (5.5)
0
3 (2.0)
2 (1.4)
Discontinued study drug due 4 (2.8)
to TEAEb
Severity of TEAEs
Mild
26 (18.4)
25 (17.1)
16 (11.1)
20 (13.5)
11 (7.5)
Moderate
18 (12.8)
22 (15.1)
10 (6.9)
17 (11.5)
10 (6.8)
Severe
7 (5.0)
5 (3.4)
0
3 (2.0)
1 (0.7)
Relationship to study drug
Related
28 (19.9)
32 (21.9)
3 (2.1)
18 (12.2)
2 (1.4)
Unrelated
23 (16.3)
20 (13.7)
23 (16.0)
22 (14.9)
20 (13.7)
Related TEAEs reported by ≥2% of participants in any treatment group
AS pain
11 (7.8)
16 (11.0)
1 (0.7)
5 (3.4)
1 (0.7)
AS dryness
9 (6.4)
8 (5.5)
2 (1.4)
9 (6.1)
0
AS exfoliation
5 (3.5)
3 (2.1)
0
2 (1.4)
1 (0.7)
AS irritation
3 (2.1)
4 (2.7)
1 (0.7)
3 (2.0)
0
AS erythema
2 (1.4)
2 (1.4)
1 (0.7)
5 (3.4)
0
AS dermatitis
2 (1.4)
3 (2.1)
0
2 (1.4)
0
AS pruritus
3 (2.1)
2 (1.4)
1 (0.7)
1 (0.7)
0
TEAEs leading to permanent withdrawal of study drug and/or early discontinuation (in ≥ 1% of participants in any treatment group)
AS pain
2 (1.4)
5 (3.4)
0
2 (1.4)
0
AS dermatitis
0
2 (1.4)
0
0
0
Sunburn
0
2 (1.4)
0
0
0
AS acne
0
0
0
0
2 (1.4)
Grade 3 (severe) cutaneous safety and tolerability assessmentsc
Scaling
0
2 (1.4)
0
2 (1.4)
0
Erythema
0
2 (1.4)
0
3 (2.0)
0
Hypopigmentation
0
0
0
0
0
Hyperpigmentation
2 (1.4)
3 (2.1)
2 (1.4)
3 (2.0)
1 (0.7)
Itching
0
1 (0.7)
0
0
1 (0.7)
Burning
6 (4.3)
8 (5.5)
0
1 (0.7)
0
Stinging
3 (2.1)
6 (4.1)
0
0
0
ADAP adapalene 0.15%, AE adverse event, AS application site, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, SAE serious adverse event, TEAE treatment-emergent adverse event
a

b
c

None of the SAEs were considered related to the study drug
One participant in the vehicle gel group discontinued the study drug, but not the study, because of a TEAE

Investigator-assessed evaluations were scaling, erythema, hypopigmentation, and hyperpigmentation; participant-assessed evaluations were
itching, burning, and stinging

multiple doses in a day) can adversely affect treatment
adherence [3, 4]. The results from the present study have
demonstrated that IDP-126 was not only well tolerated
with low rates of discontinuations due to TEAEs, it was
also efficacious and fast acting, providing significantly
greater lesion reductions vs vehicle as early as week 2.
Together with the simple once-daily treatment regimen,
this fixed-dose triple-combination may also help improve
treatment adherence.

5 Conclusions
Once-daily treatment with the novel fixed-dose triple-combination clindamycin phosphate 1.2%/BPO 3.1%/adapalene
0.15% gel (IDP-126) in an elegant delivery system demonstrated superior efficacy to vehicle gel and three dyad
component gels over 12 weeks in pediatric, adolescent, and
adult participants with moderate-to-severe acne. IDP-126
was also fast acting, significantly reducing lesion counts vs
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vehicle as early as week 2 and was safe and well tolerated.
The good efficacy and safety profiles of the only fixed-dose
triple-combination—containing three of the recommended
acne treatments (benzoyl peroxide, a topical retinoid, and a
topical antibiotic)—demonstrate that IDP-126 is a potential
new treatment option in the acne armamentarium.
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